Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete | ||
Velphoro | sucroferric oxyhydroxide | Hyperphosphatemia, end-stage renal disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | ||
Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Active | ||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
Nexavar | Sorafenib | Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) | Do not reimburse | Complete | ||
Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete |